Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.
Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...
Two new analyses of the FINEARTS-HF trial may help physicians decide how, and for whom, finerenone can best be used to treat heart failure with mildly reduced or preserved ejection fraction ...